Related Experiment Videos
Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure
1Cardiology Division, University of Utah Health Sciences Center, 50 North Medical Drive, Salt Lake City, UT 84132, USA. matthew.movsesian@hsc.utah.edu.
Abstract:
There are several reasons to believe that agents that augment cAMP-mediated signalling in cardiac myocytes should have beneficial effects in patients with heart failure. However, clinical trials of first-generation cyclic nucleotide phosphodiesterase (PDE3) inhibitors, which raise cAMP content by blocking its hydrolysis, have shown that chronic administration of these drugs affect survival adversely. The problem may be the non-selective activation of a broad spectrum of cAMP-regulated cellular responses these agents elicit. More selective (or alternatively selective) cyclic nucleotide PDE inhibitors might improve results by evoking a more restricted set of cellular responses.
Insights
Agents that boost cAMP signaling in heart cells could help heart failure patients. However, older drugs had negative survival effects due to broad cellular responses. Newer, selective inhibitors may offer better outcomes.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- Cyclic adenosine monophosphate (cAMP)-mediated signaling is crucial in cardiac myocytes.
- First-generation phosphodiesterase type 3 (PDE3) inhibitors, designed to increase cAMP, showed adverse effects on survival in heart failure patients.
- The broad activation of cellular responses by non-selective PDE3 inhibitors may explain their detrimental outcomes.
Purpose of the Study:
- To explore the potential benefits of augmenting cAMP-mediated signaling in cardiac myocytes for heart failure treatment.
- To investigate the hypothesis that non-selective activation of cellular responses by PDE3 inhibitors contributes to adverse survival effects.
- To propose that more selective or alternatively selective cyclic nucleotide PDE inhibitors could yield improved therapeutic results.
Main Methods:
- Review of existing clinical trial data for first-generation PDE3 inhibitors.
- Analysis of the cellular mechanisms underlying cAMP signaling in cardiac myocytes.
- Conceptual framework for the development of selective PDE inhibitors.
Main Results:
- Clinical trials demonstrated adverse survival effects with chronic administration of non-selective PDE3 inhibitors.
- Non-selective PDE3 inhibitors elicit a broad spectrum of cAMP-regulated cellular responses.
- The mechanism for adverse effects is linked to the widespread, non-specific cellular activation.
Conclusions:
- Augmenting cAMP signaling in cardiac myocytes holds theoretical promise for heart failure.
- Non-selective PDE inhibition carries significant risks, including adverse effects on patient survival.
- Development of selective cyclic nucleotide PDE inhibitors is a promising strategy to improve therapeutic outcomes in heart failure by targeting specific cellular responses.